These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 35455314)

  • 1. Determinants of Antibody Response to a Third SARS-CoV-2 mRNA Vaccine Dose in Solid Organ Transplant Recipients: Results from the Prospective Cohort Study COVAC-Tx.
    Balsby D; Nilsson AC; Möller S; Lindvig SO; Davidsen JR; Abazi R; Poulsen MK; Holden IK; Justesen US; Bistrup C; Johansen IS
    Vaccines (Basel); 2022 Apr; 10(4):. PubMed ID: 35455314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Humoral immune response following a third SARS-CoV-2 mRNA vaccine dose in solid organ transplant recipients compared with matched controls.
    Balsby D; Nilsson AC; Petersen I; Lindvig SO; Davidsen JR; Abazi R; Poulsen MK; Holden IK; Justesen US; Bistrup C; Johansen IS
    Front Immunol; 2022; 13():1039245. PubMed ID: 36569919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decline in Antibody Concentration 6 Months After Two Doses of SARS-CoV-2 BNT162b2 Vaccine in Solid Organ Transplant Recipients and Healthy Controls.
    Hamm SR; Møller DL; Pérez-Alós L; Hansen CB; Pries-Heje MM; Heftdal LD; Hasselbalch RB; Fogh K; Madsen JR; Almagro Armenteros JJ; Knudsen AD; Poulsen JR; Frikke-Schmidt R; Hilsted LM; Sørensen E; Ostrowski SR; Harboe ZB; Perch M; Sørensen SS; Rasmussen A; Bundgaard H; Garred P; Iversen K; Nielsen SD
    Front Immunol; 2022; 13():832501. PubMed ID: 35281023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SARS-CoV-2 anti-spike antibodies after a fourth dose of COVID-19 vaccine in adult solid-organ transplant recipients.
    Perrier Q; Lupo J; Gerster T; Augier C; Falque L; Rostaing L; Pelletier L; Bedouch P; Blanc M; Saint-Raymond C; Boignard A; Bonadona A; Noble J; Epaulard O
    Vaccine; 2022 Oct; 40(44):6404-6411. PubMed ID: 36184404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS-CoV-2 vaccine booster in solid organ transplant recipients previously immunised with inactivated versus mRNA vaccines: A prospective cohort study.
    Dib M; Le Corre N; Ortiz C; García D; Ferrés M; Martinez-Valdebenito C; Ruiz-Tagle C; Ojeda MJ; Espinoza MA; Jara A; Arab JP; Rabagliati R; Vizcaya C; Ceballos ME; Sarmiento M; Mondaca S; Viñuela M; Pastore A; Szwarcfiter V; Galdames E; Barrera A; Castro P; Gálvez NM; Soto JA; Bueno SM; Kalergis AM; Nervi B; Balcells ME
    Lancet Reg Health Am; 2022 Dec; 16():100371. PubMed ID: 36185969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Three Anti-SARS-CoV-2 Serologic Immunoassays for Post-Vaccine Response.
    Di Meo A; Miller JJ; Fabros A; Brinc D; Hall V; Pinzon N; Ierullo M; Ku T; Ferreira VH; Kumar D; Pasic MD; Kulasingam V
    J Appl Lab Med; 2022 Jan; 7(1):57-65. PubMed ID: 34342347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and Risk Factors Associated With Poor Humoral Immune Response of SARS-CoV-2 Vaccines in Recipients of Solid Organ Transplant: A Systematic Review and Meta-Analysis.
    Manothummetha K; Chuleerarux N; Sanguankeo A; Kates OS; Hirankarn N; Thongkam A; Dioverti-Prono MV; Torvorapanit P; Langsiri N; Worasilchai N; Moonla C; Plongla R; Garneau WM; Chindamporn A; Nissaisorakarn P; Thaniyavarn T; Nematollahi S; Permpalung N
    JAMA Netw Open; 2022 Apr; 5(4):e226822. PubMed ID: 35412626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
    Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
    Front Immunol; 2022; 13():863554. PubMed ID: 35711445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech).
    Korth J; Jahn M; Dorsch O; Anastasiou OE; Sorge-Hädicke B; Eisenberger U; Gäckler A; Dittmer U; Witzke O; Wilde B; Dolff S; Kribben A
    Viruses; 2021 Apr; 13(5):. PubMed ID: 33923063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in SARS-CoV-2-Specific Antibody Responses After the First, Second, and Third Doses of BNT162b2 in Naïve and Previously Infected Individuals: A 1-Year Observational Study in Healthcare Professionals.
    Ogrič M; Žigon P; Podovšovnik E; Lakota K; Sodin-Semrl S; Rotar Ž; Čučnik S
    Front Immunol; 2022; 13():876533. PubMed ID: 35711413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
    Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
    Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
    Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
    Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Humoral Response After a Second Dose of SARS-CoV-2 mRNA Vaccine in Japanese Kidney Transplant Recipients.
    Ohki Y; Kawabe M; Yamamoto I; Katsumata H; Nakada Y; Kobayashi A; Urabe F; Miki J; Yamada H; Kimura T; Matsuo N; Tanno Y; Horino T; Ohkido I; Yamamoto H; Yokoo T
    Front Microbiol; 2022; 13():922042. PubMed ID: 35756063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of SARS-CoV-2 Antibody Response 4 Weeks After Homologous vs Heterologous Third Vaccine Dose in Kidney Transplant Recipients: A Randomized Clinical Trial.
    Reindl-Schwaighofer R; Heinzel A; Mayrdorfer M; Jabbour R; Hofbauer TM; Merrelaar A; Eder M; Regele F; Doberer K; Spechtl P; Aschauer C; Koblischke M; Paschen C; Eskandary F; Hu K; Öhler B; Bhandal A; Kleibenböck S; Jagoditsch RI; Reiskopf B; Heger F; Bond G; Böhmig GA; Strassl R; Weseslindtner L; Indra A; Aberle JH; Binder M; Oberbauer R
    JAMA Intern Med; 2022 Feb; 182(2):165-171. PubMed ID: 34928302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SARS-CoV-2 Antibody Response After a Third Dose of the BNT162b2 Vaccine in Patients Receiving Maintenance Hemodialysis or Peritoneal Dialysis.
    Bensouna I; Caudwell V; Kubab S; Acquaviva S; Pardon A; Vittoz N; Bozman DF; Hanafi L; Faucon AL; Housset P
    Am J Kidney Dis; 2022 Feb; 79(2):185-192.e1. PubMed ID: 34508833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in Antibody Responses Between an Inactivated SARS-CoV-2 Vaccine and the BNT162b2 mRNA Vaccine in Solid-Organ Transplant Recipients.
    Erol Ç; Yanık Yalçın T; Sarı N; Bayraktar N; Ayvazoğlu Soy E; Yavuz Çolak M; Azap Ö; Arslan H; Haberal M
    Exp Clin Transplant; 2021 Dec; 19(12):1334-1340. PubMed ID: 34951350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Third dose of the BNT162b2 vaccine in heart transplant recipients: Immunogenicity and clinical experience.
    Peled Y; Ram E; Lavee J; Segev A; Matezki S; Wieder-Finesod A; Halperin R; Mandelboim M; Indenbaum V; Levy I; Sternik L; Raanani E; Afek A; Kreiss Y; Lustig Y; Rahav G
    J Heart Lung Transplant; 2022 Feb; 41(2):148-157. PubMed ID: 34565682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Poor humoral and T-cell response to two-dose SARS-CoV-2 messenger RNA vaccine BNT162b2 in cardiothoracic transplant recipients.
    Schramm R; Costard-Jäckle A; Rivinius R; Fischer B; Müller B; Boeken U; Haneya A; Provaznik Z; Knabbe C; Gummert J
    Clin Res Cardiol; 2021 Aug; 110(8):1142-1149. PubMed ID: 34241676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study.
    Lasagna A; Bergami F; Lilleri D; Percivalle E; Quaccini M; Alessio N; Comolli G; Sarasini A; Sammartino JC; Ferrari A; Arena F; Secondino S; Cicognini D; Schiavo R; Lo Cascio G; Cavanna L; Baldanti F; Pedrazzoli P; Cassaniti I
    ESMO Open; 2022 Apr; 7(2):100458. PubMed ID: 35427842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of the BNT162b2 mRNA vaccine in heart transplant recipients - a prospective cohort study.
    Itzhaki Ben Zadok O; Shaul AA; Ben-Avraham B; Yaari V; Ben Zvi H; Shostak Y; Pertzov B; Eliakim-Raz N; Abed G; Abuhazira M; Barac YD; Mats I; Kramer MR; Aravot D; Kornowski R; Ben-Gal T
    Eur J Heart Fail; 2021 Sep; 23(9):1555-1559. PubMed ID: 33963635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.